metformin has been researched along with Parkinsonian Disorders in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin has antidepressant and antiparkinsonian potential due to anti-inflammatory neurogenic, and neuroplasticity-inducing effects when combined with fluoxetine." | 1.72 | Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. ( Costa, BLDSAD; Duarte-Silva, EP; Melo, MG; Mendonça, IP; Oliveira, WH; Paiva, IHR; Peixoto, CA; Silva, RSD, 2022) |
| "Metformin is a widely used oral antidiabetic drug with known anti-inflammatory properties due to its action on AMPK protein." | 1.43 | Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system. ( de Pablos, RM; Espinosa-Oliva, AM; García-Quintanilla, A; Herrera, AJ; Ismaiel, AA; Oliva-Martín, MJ; Santiago, M; Venero, JL, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, IP | 1 |
| Paiva, IHR | 1 |
| Duarte-Silva, EP | 1 |
| Melo, MG | 1 |
| Silva, RSD | 1 |
| Oliveira, WH | 1 |
| Costa, BLDSAD | 1 |
| Peixoto, CA | 1 |
| Ismaiel, AA | 1 |
| Espinosa-Oliva, AM | 1 |
| Santiago, M | 1 |
| García-Quintanilla, A | 1 |
| Oliva-Martín, MJ | 1 |
| Herrera, AJ | 1 |
| Venero, JL | 1 |
| de Pablos, RM | 1 |
2 other studies available for metformin and Parkinsonian Disorders
| Article | Year |
|---|---|
Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity.
Topics: Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Depression; Drug Therapy, Comb | 2022 |
Metformin, besides exhibiting strong in vivo anti-inflammatory properties, increases mptp-induced damage to the nigrostriatal dopaminergic system.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Cell Culture Techniques; Cell Line; Corpus Striatum; D | 2016 |